Salute e Benessere

Implantica adds another RefluxStop™ center in Spain

"I appreciate the innovative approach that RefluxStop™ brings to the surgical treatment of GERD, correcting the body's natural anatomy to bring back normal function," says Dr. Priego, who goes on to say, "RefluxStop™ joins the therapeutic arsenal that will allow an effective corrective surgical treatment that reduces the side effects of standard anti-reflux surgery." "I appreciate the innovative approach that RefluxStop™ brings to the surgical treatment of GERD…
PR Newswire
18/12/2023

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop…

Biocytogen will receive an upfront payment for granting the option, and will be further entitled to an option-exercise fee, development and commercialization milestone payments, as well as single-digit royalties on net sales once Ona elects to exercise the option in full. Biocytogen will receive an upfront payment for granting the option, and will be further entitled to an option-exercise fee, development and commercialization milestone payments, as well as single-digit royalties on net sales...
PR Newswire
18/12/2023

Major new vaccines initiative aims to fight deadly airborne infections

Professor Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, sees great potential for NIVI, both in Denmark and globally. ProfessorMads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, sees great potential for NIVI, both inDenmarkand globally. "The development of the Covid-19 vaccines demonstrated the extraordinary possibilities when interdisciplinary vaccine research and development are prioritised," says Krogsgaard Thomsen. "With NIVI, the Novo Nordisk…
PR Newswire
18/12/2023

Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470…

Press ReleaseNicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in GlaucomaDecember 18, 2023 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the first patient has been screened in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular...
Nasdaq GlobeNewswire
18/12/2023

Santhera's AGAMREE® (Vamorolone) Approved in the European Union for the…

European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EUFirst commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth...
Nasdaq GlobeNewswire
18/12/2023

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

NEWS RELEASE – REGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on NasdaqIRVINE, CA, and HERSTAL, BELGIUM– December 18, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listing on Nasdaq.In accordance with prior announcements made by the...
Nasdaq GlobeNewswire
18/12/2023

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Mithra Receives Positive DSMB Opinion on DONESTA ®European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program has previously reported positive top-line data; extension to Europe trial ongoingAdditional endometrial data analyses ongoing for inclusion in regulatory submissionsMithra plans to submit DONESTA® for approval by U.S. and European regulators in Q4 2024Liege, Belgium, 18...
Nasdaq GlobeNewswire
18/12/2023

Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET…

Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with vaccine specific T cell responses, meeting the secondary endpointIn addition to the trial results, advancements in preclinical research, technology development and product manufacturing provide a valuable foundation for the future development of the TET technology platform and TET-based vaccine...
Nasdaq GlobeNewswire
18/12/2023

Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research…

D.O.R.C., a leading player in the retinal surgical devices market, will be a key contributor to ZEISS Medical Technology's long-term strategy and success going forward. With the acquisition, ZEISS will expand its position in the vitreo-retinal (VR) surgery segment, further strengthening its position as the fastest growing manufacturer of ophthalmic medical devices globally. D.O.R.C.'s products are used by ophthalmic surgeons around the world to treat a wide range of vision-threatening…
PR Newswire
15/12/2023

Incretin-based Drugs Market to Reach $73.9 billion, globally, by 2032 at 7.9%…

Request Sample of the Report on Incretin-based Drugs Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/657 Request Sample of the Report on Incretin-based Drugs Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/657 Prime determinants of growth Key factors driving the growth of the Incretin-based drugs market includes the increasing prevalence of diabetes, particularly type 2 diabetes, across the globe. As more people are diagnosed...
PR Newswire
15/12/2023

Cartilage Repair / Cartilage Regeneration Market Worth $2.8 billion |…

Browse in-depth TOC on "Cartilage Repair / Cartilage Regeneration Market" Browse in-depth TOC on "Cartilage Repair / Cartilage Regeneration Market" 136 - Tables 33 - Figures 160 - Pages Cartilage Repair / Cartilage Regeneration Market Scope: Treatment modality segment is expected to account for the largest share in 2022. By treatment modality the Cartilage Repair/Cartilage Regeneration market is divided into Cell-based and non-cell-based categories where...
PR Newswire
15/12/2023

Clinical Trial Services Market to Exhibit Significant Growth at 6.11% CAGR…

Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/clinical-trial-services-market-269 Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/clinical-trial-services-market-269 Trending Now: Medable and Pluto Health Team Up to Revolutionize Clinical Trials Medable and Pluto Health announced their alliance inOctober 2023to revolutionize clinical trials. Medable, a company well-known for its cutting-edge digital clinical trial...
PR Newswire
15/12/2023

Patient Engagement Solutions Market Worth $41.8 Billion | MarketsandMarkets

Browse in-depth TOC on "Patient Engagement Solutions Market" Browse in-depth TOC on "Patient Engagement Solutions Market" 150 - Tables 30 - Figures 206 - Pages Patient Engagement Solutions Market Scope: "The Software segment is estimated to account for the largest share of the Patient Engagement Solutions market in 2023." On the basis of components, the patient engagement solutions market is bifurcated into software, hardware (into in-room television, integrated...
PR Newswire
15/12/2023

Protein Assays Market to Reach $4,449.02 Million, Globally, by 2032 at 6.5%…

Request Sample of the Report on Protein Assays Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/6552 Request Sample of the Report on Protein Assays Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/6552 Prime determinants of growth The increase in incidence of chronic disease is escalating demand for advance diagnostic measures and rise in the number of R&D activities in the field of proteomics acts as a key driving factor...
PR Newswire
15/12/2023

CHMP Issues Positive Opinion for Biogen's SKYCLARYS® (omaveloxolone), the First…

Friedreich's ataxia is a genetic, debilitating and life-shortening neuromuscular disease 1 Milestone highlights Biogen's growing portfolio in rare diseases and focus on addressing unmet needs of patients living with neuromuscular diseases CAMBRIDGE, Mass., Dec.15, 2023(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS ®...
Nasdaq GlobeNewswire
15/12/2023

Curia Appoints Gerald Auer as Chief Financial Officer

“I am delighted to welcome Gerald to Curia as we head into the new year," said Curia CEO Philip Macnabb. “Gerald brings extensive experience leading finance divisions with an impressive track record for success. I am confident that he will be an invaluable asset to our team and will help position us for a strong year in 2024.”Auer most recently served as CFO at Al Dahra, a company specializing in agribusiness. Prior to his time at Al Dahra, Auer was CFO of the EMEA crop science division...
Nasdaq GlobeNewswire
15/12/2023

Zymeworks Added to Nasdaq Biotechnology Index

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is...
Nasdaq GlobeNewswire
15/12/2023

Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of…

/6 inhibitor. “We continue to make great progress in evaluating the combination of samuraciclib and fulvestrant with the dosing of the first patient in the Phase 2b study,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “There is a large unmet need in treatment for women with HR+, HER2- breast cancer, which represents more than two thirds of all new female breast cancer cases. We previously announced data from a single-arm Ph2a study with this combination therapy that...
Nasdaq GlobeNewswire
15/12/2023

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023– AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share.The Company expects the gross proceeds from the offering, before deducting the...
Nasdaq GlobeNewswire
15/12/2023

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease…

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b TrialPotentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally 1with preclinical ADAC...
Nasdaq GlobeNewswire
15/12/2023

Tianlong Solution Facilitates the Prevention and Control of Livestock Diseases

Tianlong's livestock disease detection solution comprises a range of instruments including GeneRotex 96 Nucleic Acid Extractor, Libex Nucleic Acid Extractor, Gentier 96E/96R Real-Time PCR System, and Gentier Mini Series Portable Real-Time PCR System. These instruments exhibit outstanding performance in pathogene nucleic acid detection, guaranteeing the ability to quickly obtain precise, stable, and reliable outcomes, which enhances detection efficiency significantly. Multiple throughput can also…
PR Newswire
15/12/2023

Star 12000: A Visual Masterpiece Redefining Vaping in the Middle East

The Star 12000 transcends conventional functionality to emerge as a piece of art. Its marbling design redefines minimalism with fluidity, satisfying the Middle Eastern customer's penchant for style and aesthetics. Positioned as a trendsetter in the local vaping industry, the Star 12000 not only catches the eye but also offers a cost-efficient way for UAE users to indulge in a sophisticated nicotine experience. The Star 12000 transcends conventional functionality to emerge as a piece of art...
PR Newswire
15/12/2023

Sectra's six-month interim report 2023/2024: Strong performance in all operating…

Six-month period (May–October 2023) in figures Six-month period (May–October 2023) in figures Comments from Torbjörn Kronander, President and CEO of Sectra AB"Our most valuable asset is our customers' confidence in our ability to deliver the best possible quality and in our employees' expertise. We drive innovation through partnerships with customers and various players in the industry. These partnerships aren't just about research and development, or integration with systems from other...
PR Newswire
15/12/2023

Saved By the Smell - IDTechEx Explores Environmental Gas Sensors

Being health-conscious can be taken to a new level, as air quality is becoming a new variable to consider next to daily step count. Smart gadgets such as phones and watches fitted with wearable sensors could soon allow people to be notified when their heart rate or stress levels are increased in correlation with poor air quality, advising an alternative route to walk, helping people make better decisions for their health. Being health-conscious can be taken to a new level, as air quality is...
PR Newswire
15/12/2023
Altri  Comunicati